Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application filed by its subsidiary Hebei Wanbang Folon Pharmaceutical for Tao Hong Si Wu Tang Granules. The move underlines the group’s continued push into innovative traditional Chinese medicine and could broaden its women’s health portfolio in the Chinese market.
The product is classified as a Category 3.1 innovative traditional Chinese medicine, based on the classical Tao Hong Si Wu Decoction listed in the national catalogue of ancient classic formulas. It is intended for treating blood deficiency and blood stasis syndromes associated with gynecological conditions such as irregular menstruation and painful, clot-heavy periods, potentially strengthening Fosun Pharma’s position in evidence-based traditional formulations.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group engaged in pharmaceutical manufacturing, research and development, and related medical services. The company operates through multiple subsidiaries and focuses on innovative drugs and therapies, with an active presence in both traditional Chinese medicine and modern pharmaceuticals in domestic and overseas markets.
Average Trading Volume: 2,601,597
Technical Sentiment Signal: Sell
Current Market Cap: HK$72.19B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.